Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

plasmapheresis and anti-CD20 monoclonal antibody therapy, are occasionally employed. Immunosuppressants used to treat pemphigus include azathioprine, cyclophosphamide, cyclosporine, mycophenolate ...

It licensed the compound, an anti-CD20 mAb, to London-based GlaxoSmithKline in late 2006. The entire development process, from generating a hybridoma cell line to final approval, took seven years ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

Pemphigus is a rare autoimmune disease that causes painful blisters on the skin and mucous membranes, including the mouth, ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Tecfidera is believed to have anti-inflammatory and antioxidant properties ... Briumvi (ublituximab) is a monoclonal antibody that targets CD20-positive lymphocytes. Briumvi is approved for the ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.